These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 8199996

  • 1. Activation of cellular immunity after intracavitary monoclonal antibody therapy of ovarian cancer.
    Kosmas C, Epenetos AA, Courtenay-Luck NS.
    Cancer; 1994 Jun 15; 73(12):3000-10. PubMed ID: 8199996
    [Abstract] [Full Text] [Related]

  • 2. Patients receiving murine monoclonal antibody therapy for malignancy develop T cells that proliferate in vitro in response to these antibodies as antigens.
    Kosmas C, Epenetos AA, Courtenay-Luck NS.
    Br J Cancer; 1991 Sep 15; 64(3):494-500. PubMed ID: 1911190
    [Abstract] [Full Text] [Related]

  • 3. Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody.
    Herold KC, Bluestone JA, Montag AG, Parihar A, Wiegner A, Gress RE, Hirsch R.
    Diabetes; 1992 Mar 15; 41(3):385-91. PubMed ID: 1532369
    [Abstract] [Full Text] [Related]

  • 4. Mitogenic activity of anti-CD28 MoAb CLB-CD28/1 on peripheral blood mononuclear cells and its cooperation with other anti-T cells MoAb in the activation of purified T lymphocytes.
    De Felice M, Giarrusso PC, Lamberti A, Turco MC, Valerio G, van Lier RA, Yang SY, Ferrone S, Venuta S.
    Tissue Antigens; 1990 Jul 15; 36(1):12-8. PubMed ID: 1701062
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes.
    Lamers CH, Gratama JW, Warnaar SO, Stoter G, Bolhuis RL.
    Int J Cancer; 1995 Feb 08; 60(4):450-7. PubMed ID: 7829257
    [Abstract] [Full Text] [Related]

  • 6. [In vitro study of the antitumor immune responses induced by anti-idiotypic minibody vaccine of ovarian cancer].
    Chang XH, Cui H, Feng J, Yang WL, Li Y, Fu TY, Ye X, Zhu HL, Cheng HY, Cheng YX, Guo HF.
    Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Oct 18; 37(5):480-4. PubMed ID: 16224517
    [Abstract] [Full Text] [Related]

  • 7. Study of induction of activation of human peripheral blood mononuclear cells with a non-activating form of anti-CD3 MoAb in autoimmune thyroid disease (AITD).
    Resetkova E, Arreaza G, Yoshikawa N, Morita T, Kim H, Carayon P, Volpé R.
    Clin Exp Immunol; 1993 Mar 18; 91(3):397-403. PubMed ID: 8443962
    [Abstract] [Full Text] [Related]

  • 8. [Interleukin-12 restores and promotes the T-cell immune function inhibited by 5-fluorouracil].
    Chi PD, Li L, Fan YY, Wu CY.
    Ai Zheng; 2007 Aug 18; 26(8):801-8. PubMed ID: 17697537
    [Abstract] [Full Text] [Related]

  • 9. In vivo administration of anti-murine CD3 monoclonal antibody induces selective, long-term anergy in CD8+ T cells.
    Woodle ES, Hussein S, Bluestone JA.
    Transplantation; 1996 Mar 15; 61(5):798-803. PubMed ID: 8607186
    [Abstract] [Full Text] [Related]

  • 10. Differential T cell hyporesponsiveness induced by in vivo administration of intact or F(ab')2 fragments of anti-CD3 monoclonal antibody. F(ab')2 fragments induce a selective T helper dysfunction.
    Hirsch R, Archibald J, Gress RE.
    J Immunol; 1991 Oct 01; 147(7):2088-93. PubMed ID: 1833451
    [Abstract] [Full Text] [Related]

  • 11. [Specific immune cell therapy against ovarian cancer in vivo and in vitro].
    Chang XH, Cheng HY, Cheng YX, Ye X, Guo HF, Fu TY, Zhang L, Zhang G, Cui H.
    Ai Zheng; 2008 Dec 01; 27(12):1244-50. PubMed ID: 19079987
    [Abstract] [Full Text] [Related]

  • 12. Combination anti-CD2 and anti-CD3 monoclonal antibodies induce tolerance while altering interleukin-2, interleukin-4, tumor necrosis factor, and transforming growth factor-beta production.
    Chavin KD, Qin L, Lin J, Woodward JE, Baliga P, Bromberg JS.
    Ann Surg; 1993 Oct 01; 218(4):492-501; discussion 501-3. PubMed ID: 8215640
    [Abstract] [Full Text] [Related]

  • 13. Differences between primed allogeneic T-cell responses and the primary mixed leucocyte reaction. Primed T cells become independent of the blocking effects of monoclonal antibodies against IL-1 beta and the CD5, CD11a (LFA-1), and CD11c (p 150,95) molecules.
    Odum N, Hofmann B, Morling N, Platz P, Ryder LP, Tvede N, Geisler C, Svejgaard A.
    Scand J Immunol; 1988 Apr 01; 27(4):405-11. PubMed ID: 2966435
    [Abstract] [Full Text] [Related]

  • 14. Major injury induces increased production of interleukin-10 by cells of the immune system with a negative impact on resistance to infection.
    Lyons A, Kelly JL, Rodrick ML, Mannick JA, Lederer JA.
    Ann Surg; 1997 Oct 01; 226(4):450-8; discussion 458-60. PubMed ID: 9351713
    [Abstract] [Full Text] [Related]

  • 15. Monoclonal antibodies that inhibit activation and proliferation of lymphocytes. II. Requisite role of the monoclonal antibody-defined antigen systems in activation and proliferation of human and rat lymphocytes.
    Yagita H, Hashimoto Y.
    J Immunol; 1986 Mar 15; 136(6):2062-8. PubMed ID: 2419421
    [Abstract] [Full Text] [Related]

  • 16. Induction of interleukin 2 receptiveness and proliferation in resting peripheral T cells by monoclonal anti-CD3 (T3) antibodies does not require the presence of macrophages.
    Stingl LA, Sinska A, Landesmann U, Smolen JS.
    Clin Exp Immunol; 1987 Apr 15; 68(1):146-55. PubMed ID: 3115639
    [Abstract] [Full Text] [Related]

  • 17. Possible involvement of the CD4 molecule in a late activation event on CD4+ T cell proliferation in the human autologous mixed lymphocyte reaction.
    Sakane T, Takada S.
    Clin Exp Immunol; 1989 Feb 15; 75(2):269-74. PubMed ID: 2522840
    [Abstract] [Full Text] [Related]

  • 18. Signal requirements for activation of leukaemic T cells from a chronic lymphocytic leukaemia (T-CLL).
    Zocchi MR, Poggi A, Heltai S, Villa A, Inverardi L, Vicari A, Sabbadini MG, Ferrarini M.
    Clin Exp Immunol; 1990 Oct 15; 82(1):108-13. PubMed ID: 1976463
    [Abstract] [Full Text] [Related]

  • 19. [Lymphocyte activation markers in patients with ovarian cancer].
    Nowicka A, Rogala E, Bednarek W, Barczyński B, Wertel I, Piekarczyk W, Kotarski J.
    Ginekol Pol; 2012 Oct 15; 83(10):737-43. PubMed ID: 23383558
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.